A5101452238- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Esophageal Cancer Research and Treatment
- Breast Lesions and Carcinomas
- Cancer Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Chemotherapy-related skin toxicity
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Cancer-related Molecular Pathways
- RNA modifications and cancer
- Estrogen and related hormone effects
- Cancer Cells and Metastasis
- Radiopharmaceutical Chemistry and Applications
- Cell Adhesion Molecules Research
- CAR-T cell therapy research
- Metastasis and carcinoma case studies
- Genetic factors in colorectal cancer
Chinese Academy of Medical Sciences & Peking Union Medical College
2016-2025
Cancer Hospital of Chinese Academy of Medical Sciences
2009-2024
Peking Union Medical College Hospital
2013-2024
Zhejiang Chinese Medical University
2024
Chinese Academy of Sciences
2023
National Clinical Research
2018-2022
Beijing Tsinghua Chang Gung Hospital
2020
Tsinghua University
2020
Molecular Oncology (United States)
2018-2019
Academy of Medical Sciences
2010-2019
Background Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growth factor 2–positive breast cancer and increases the pathologic complete response in neoadjuvant setting, but their role as adjuvant therapy remains uncertain. Methods In Adjuvant and/or Trastuzumab Treatment Optimization trial, patients with centrally confirmed early were randomly assigned to 1 year of T, L, sequence (T→L), or combination (L+T). The primary end point was disease-free survival...
Pyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity and acceptable tolerability in a phase I trial. We assessed the efficacy of pyrotinib versus lapatinib, both combination with capecitabine, women human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer open-label, multicenter, randomized II study.Chinese patients HER2-positive relapsed or previously treated taxanes, anthracyclines, and/or trastuzumab were assigned (1:1) to receive 400...
Apatinib is an oral, highly potent tyrosine-kinase inhibitor targeting VEGFR2. Phase I study showed the recommended dose of 750 mg/day with substantial antitumor activity. This phase II aims to evaluate optimum level for efficacy and safety apatinib monotherapy in heavily pretreated patients metastatic triple negative breast cancer (mTNBC) China. IIa was first performed among 25 previously treated anthracycline and/or taxane. All received p.o. a 4-week cycle. Subsequently, IIb 59 activated,...
We sought to determine whether the combination of ixabepilone plus capecitabine improved overall survival (OS) compared with alone in patients metastatic breast cancer (MBC) previously treated anthracyclines and taxanes.A total 1,221 MBC anthracycline taxanes were randomly assigned (40 mg/m(2) intravenously on day 1) (2,000 orally days 1 through 14) or (2,500 same schedule) given every 21 days. The trial was powered detect a 20% reduction hazard ratio (HR) for death.There no significant...
LBA4 Background: Lapatinib (L) is a HER1-HER2 tyrosine kinase inhibitor. The Adjuvant and/or Trastuzumab Treatment Optimisation (ALTTO) Trial randomised, phase III trial comparing 3 oral L-containing regimens with T, each given for 1 year. Methods: From June 2007 to July 2011, 8381 patients (pts) were randomised from 946 sites in 44 countries receive either L+T, T→L, L, or T. Anti-HER2 therapy was initiated after completing all chemotherapy (N=4613), concurrently taxane following...
Lapatinib is an oral small-molecule tyrosine kinase inhibitor of both epidermal growth factor receptor and human 2 (HER2). This study designed to test whether the addition lapatinib paclitaxel improves overall survival (OS) compared with placebo plus in patients HER2-overexpressing metastatic breast cancer (MBC).This phase III, randomized, double-blind assessed efficacy safety newly diagnosed HER2-positive MBC. The primary end point was OS. Secondary points included progression-free (PFS),...
Neratinib is a potent irreversible pan-tyrosine kinase inhibitor with antitumor activity and acceptable tolerability in patients human epidermal growth factor receptor 2 (HER2) -positive breast cancer. A multinational, open-label, phase I/II trial was conducted to determine the maximum-tolerated dose (MTD) of neratinib plus capecitabine solid tumors (part one) evaluate safety efficacy HER2-positive metastatic cancer two).Part one 3 + dose-escalation study which advanced received oral once...
Abstract Background Epithelial–mesenchymal transition (EMT) is implicated in the metastatic process and presents a challenge to epithelial cell adhesion molecule‐based detection of circulating tumor cells (CTCs), which have been demonstrated be prognostic indicator breast cancer. Although evidence has indicated that heterogeneity CTCs based on EMT markers associated with disease progression, no standard recommendations established for clinical practice. This study aimed evaluate significance...
Abstract Background Disitamab vedotin (DV; RC48‐ADC) is an antibody‐drug conjugate comprising a human epidermal growth factor receptor 2 (HER2)‐directed antibody, linker and monomethyl auristatin E. Preclinical studies have shown that DV demonstrated potent antitumor activity in preclinical models of breast, gastric, ovarian cancers with different levels HER2 expression. In this pooled analysis, we report the safety efficacy patients HER2‐overexpression HER2‐low advanced breast cancer (ABC)....
Neratinib is a potent irreversible pan-ErbB tyrosine kinase inhibitor that has demonstrated antitumour activity and an acceptable safety profile in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer other solid tumours. This was phase I/II, open-label, two-part study. Part 1 dose-escalation study to determine the maximum tolerated dose (MTD) of neratinib plus paclitaxel 2 evaluated safety, efficacy, pharmacokinetics combination at MTD HER2-positive cancer....
The objective of this study was to evaluate the efficacy and safety eribulin monotherapy, relative vinorelbine, in Chinese women with locally recurrent/metastatic breast cancer (MBC).This phase III open-label, randomised, parallel-group, multicentre clinical trial enrolled patients recurrent or MBC who had 2-5 prior chemotherapy regimens, including an anthracycline taxane) from September 26, 2013, May 19, 2015. Women were randomised 1:1 receive (1.4 mg/m2, intravenously, on day 1 8)...
Tumor heterogeneity was associated with treatment outcome of metastatic cancers but few studies have examined whether tumor in circulating DNA (ctDNA) can be used to predict outcome. ctDNA analysis performed 37 HER2‐positive breast cancer patients treated pyrotinib. Patients high had significantly worse PFS outcomes, a median 30.0 weeks vs . 60.0 for low (hazard ratio [HR], 2.9; p = 0.02). trunk resistance mutations receiving pyrotinib monotherapy outcomes (HR, 4.5; 0.03), 7.8 27.4 those...
Background The clinical response to anti–programmed cell death 1 (PD‐1) antibodies in patients with advanced gastric and gastroesophageal junction (GEJ) cancer China has not been reported. Methods This study evaluated the efficacy safety of SHR‐1210, an anti–PD‐1 antibody, gastric/GEJ a phase trial. associations between candidate biomarkers (programmed ligand [PD‐L1] expression, mismatch repair status, tumor mutation load, lactate dehydrogenase [LDH] levels) SHR‐1210 were also explored....
// Anjie Zhu 1 , Peng Yuan Feng Du Ruoxi Hong 2 Xiaoyan Ding 3 Xiuqing Shi 4 Ying Fan Jiayu Wang Yang Luo Fei Ma Pin Zhang Qing Li Binghe Xu Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy Sciences and Peking Union College(CAMS&PUMC), Beijing, China Sun Yat-sen University center, The State Key Laboratory Oncology in South China, Collaborative Innovation Center for Medicine, Guangzhou, Guangdong, Beijing Ditan Capital University, Yuhuangding Yantai,...
Human epidermal growth factor receptor 2 (HER2) protein overexpression or gene amplification is an important predictive biomarker for identifying patients with breast cancer, who may benefit from HER2-targeted therapy. However, little known about the molecular landscape and efficacy of therapy in HER2-mutated metastatic cancer. We analysed HER2 mutation features 1184 invasive In addition, a single-arm, prospective, phase-II study (NCT03412383) pyrotinib was conducted patient...
Abstract Circulating tumor DNA (ctDNA) is a potential biomarker of prognosis and therapeutic response. We conducted this study to explore the role molecular burden index (mTBI) in ctDNA as response prognostic larger cohort prospective phase III randomized multicenter study. collected 291 plasma samples from 125 metastatic breast cancer patients CAMELLIA (NCT01917279). Target-capture deep sequencing 1021 genes was performed detect somatic variants samples. The pretreatment mTBI value...
Importance Understanding the detailed symptom spectrum of chemotherapy-induced peripheral neuropathy (CIPN) could facilitate shared decision-making and promote early intervention. Objective To compare patient-reported CIPN associated with nab-paclitaxel, paclitaxel, docetaxel treatments among patients breast cancer. Design, Setting, Participants This prospective cohort study was conducted at 9 medical centers across China from 2019 to 2021. included hospitalized women diagnosed invasive...